[1] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
[2] Waldo AL, Camm AJ, deRuyter H, et al. Survival with oral d- sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995; 75: 1023-1027.
[3] Kaneko N. New 1,4-benzothiazepine derivative, K201, demon- strates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action. Drug Dev Res 1994; 33: 429.
[4] Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 1999; 79: 275- 281.
[5] Kiriyama K, Kiyosue T, Wang JC, Dohi K, Arita M. Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K+ current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 646-653.
[6] Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H. In- hibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts. Br J Pharmacol 2000; 131: 1363-1372.
[7] Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
[8] Wehrens XH, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein cal- stabin2. Science 2004; 304: 292-296.
[9] Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000; 101: 365-376.
[10] Wehrens XH, Marks AR. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Discov 2004; 3: 565-573.
[11] Yano M, Kobayashi S, Kohno M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003; 107: 477-484.
[12] Xiao J, Tian X, Jones PP, et al. Removal of FKBP12.6 does not alter the conductance and activation of the cardiac ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmias. J Biol Chem 2007; 282: 34828-34838.
[13] Kohno M, Yano M, Kobayashi S, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H1035-1042.
[15] Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 2002; 90: 309-316.
[16] Oda T, Yano M, Yamamoto T, et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 2005; 111: 3400- 3410.
[17] Cheng H, Lederer MR, Lederer WJ, Cannell MB. Calcium sparks and [Ca2+]i waves in cardiac myocytes. Am J Physiol 1996; 270: C148-159.
[18] Trafford AW, O'Neill SC, Eisner DA. Factors affecting the propa- gation of locally activated systolic Ca transients in rat ventricular myocytes. Pflugers Arch 1993; 425: 181-183.
[19] Boyden PA, Dun W, Barbhaiya C, Ter Keurs HE. 2APB- and JTV519(K201)-sensitive micro Ca2+ waves in arrhythmogenic Purkinje cells that survive in infarcted canine heart. Heart Rhythm 2004; 1: 218-226.
[20] Loughrey CM, Otani N, Seidler T, et al. K201 modulates excitation-contraction coupling and spontaneous Ca2+ release in normal adult rabbit ventricular cardiomyocytes. Cardiovasc Res 2007; 76: 236-246.
[21] Schlaepfer DD, Mehlman T, Burgess WH, Haigler HT. Structural and functional characterization of endonexin II, a calcium- and phospholipid-binding protein. Proc Natl Acad Sci USA 1987; 84: 6078-6082.
[22] Khanna NC, Helwig ED, Ikebuchi NW, et al. Purification and characterization of annexin proteins from bovine lung. Biochemis- try 1990; 29: 4852-4862.
[23] Kobayashi R, Nakayama R, Ohta A, et al. Identification of the 32 kDa components of bovine lens EDTA-extractable protein as endonexins I and II. Biochem J 1990; 266: 505-511.
[24] Kaneko N, Ago H, Matsuda R, Inagaki E, Miyano M. Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor. J Mol Biol 1997; 274: 16-20.
[25] Kaneko N, Matsuda R, Toda M, Shimamoto K. Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative. Biochim Biophys Acta 1997; 1330: 1-7.
[26] Yamamoto T, Yano M, Xu X, et al. Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts. Circulation 2008; 117: 762-772.
[27] Kheifets V, Bright R, Inagaki K, Schechtman D, Mochly-Rosen D. Protein kinase C delta (deltaPKC)-annexin V interaction: a required 
[29] Kaneko N, Matsuda R, Ohtani N, et al. K201 improved norepinephrine-induced diastolic dysfunction with preserved ejection fraction. Drug Dev Res 2006; 67: 852.
[30] Eberli FR, Stromer H, Ferrell MA, et al. Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts. Circulation 2000; 102: 2643-2649.
[31] Kumagai K, Nakashima H, Gondo N, Saku K. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrilla- tion/flutter in a canine sterile pericarditis model. J Cardiovasc Elec- trophysiol 2003; 14: 880-884.
[32] Chen YJ, Chen YC, Wongcharoen W, Lin CI, Chen SA. Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes. Br J Pharmacol 2008; 153: 915-925.